Cover Image
市場調查報告書

膜性腎小球腎炎:全球臨床實驗趨勢

Membranous Glomerulonephritis Global Clinical Trials Review, H2, 2017

出版商 GlobalData 商品編碼 602470
出版日期 內容資訊 英文 41 Pages
訂單完成後即時交付
價格
Back to Top
膜性腎小球腎炎:全球臨床實驗趨勢 Membranous Glomerulonephritis Global Clinical Trials Review, H2, 2017
出版日期: 2017年12月28日 內容資訊: 英文 41 Pages
簡介

本報告提供膜性腎小球腎炎治療藥臨床實驗相關的基本數據和資料,彙整實驗數量及受驗者的募集情況,各階段趨勢,實施臨床實驗的主要製藥企業及研究機關的簡介等資料。

本報告概要

調查範圍

各地區的臨床實驗情形

  • 各國臨床實驗數量和平均實驗人數
    • 亞太地區主要5國的臨床實驗數量
    • 歐洲主要5國的臨床實驗數量
    • 北美主要國家的臨床實驗數量

G7各國臨床實驗數量:泌尿生殖系統系及性荷爾蒙治療藥臨床實驗上膜性腎小球腎炎的比例

G7各國的各階段臨床實驗數量

G7各國臨床實驗數量:各進展狀況

E7各國臨床實驗數量:泌尿生殖系統系及性荷爾蒙治療藥臨床實驗上膜性腎小球腎炎的比例

E7各國的各階段臨床實驗數量

E7各國臨床實驗數量:各進展狀況

各階段臨床實驗數量

  • 進行中的臨床實驗:各階段

各進展狀況臨床實驗數量

臨床實驗的目標達成情形

一定期間所採用的實驗對象

贊助商類別的臨床實驗數量

有潛力的贊助商

膜性腎小球腎炎治療藥臨床實驗主要的參與企業

有潛力的藥劑

臨床實驗簡介概要

附錄

目錄
Product Code: GDHC4769CTIDB

GlobalData's clinical trial report, "Membranous Glomerulonephritis Global Clinical Trials Review, H2, 2017" provides an overview of Membranous Glomerulonephritis clinical trials scenario. This report provides top line data relating to the clinical trials on Membranous Glomerulonephritis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table of Contents

Table of Contents 2

  • List of Tables 3
  • List of Figures 4
  • Report Guidance 5
  • GlobalData Clinical Trials Report Coverage 6
  • Clinical Trials by Region 7
  • Clinical Trials and Average Enrollment by Country 8
  • Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
  • Top Five Countries Contributing to Clinical Trials in Europe 11
  • Top Countries Contributing to Clinical Trials in North America 12
  • Clinical Trials by G7 Countries: Proportion of Membranous Glomerulonephritis to Genito Urinary System And Sex Hormones Clinical Trials 13
  • Clinical Trials by Phase in G7 Countries 14
  • Clinical Trials in G7 Countries by Trial Status 15
  • Clinical Trials by E7 Countries: Proportion of Membranous Glomerulonephritis to Genito Urinary System And Sex Hormones Clinical Trials 16
  • Clinical Trials by Phase in E7 Countries 17
  • Clinical Trials in E7 Countries by Trial Status 18
  • Clinical Trials by Phase 19
  • In Progress Trials by Phase 20
  • Clinical Trials by Trial Status 21
  • Clinical Trials by End Point Status 22
  • Subjects Recruited Over a Period of Time 23
  • Clinical Trials by Sponsor Type 24
  • Prominent Sponsors 25
  • Top Companies Participating in Membranous Glomerulonephritis Therapeutics Clinical Trials 26
  • Prominent Drugs 27
  • Clinical Trial Profile Snapshots 28
  • Appendix 39
  • Abbreviations 39
  • Definitions 39
  • Research Methodology 40
  • Secondary Research 40
  • About GlobalData 41
  • Contact Us 41
  • Source 41

List of Tables

  • Membranous Glomerulonephritis Therapeutics, Global, Clinical Trials by Region, 2017* 7
  • Membranous Glomerulonephritis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 8
  • Membranous Glomerulonephritis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 9
  • Membranous Glomerulonephritis Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2017* 10
  • Membranous Glomerulonephritis Therapeutics Clinical Trials, Europe, Top Five Countries, 2017* 11
  • Membranous Glomerulonephritis Therapeutics Clinical Trials, North America, Top Countries, 2017* 12
  • Proportion of Membranous Glomerulonephritis to Genito Urinary System And Sex Hormones Clinical Trials, G7 Countries (%), 2017* 13
  • Membranous Glomerulonephritis Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 14
  • Membranous Glomerulonephritis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 15
  • Proportion of Membranous Glomerulonephritis to Genito Urinary System And Sex Hormones Clinical Trials, E7 Countries (%), 2017* 16
  • Membranous Glomerulonephritis Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 17
  • Membranous Glomerulonephritis Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 18
  • Membranous Glomerulonephritis Therapeutics, Global, Clinical Trials by Phase, 2017* 19
  • Membranous Glomerulonephritis Therapeutics, Global, Clinical Trials In Progress by Phase 2017* 20
  • Membranous Glomerulonephritis Therapeutics, Global, Clinical Trials by Trial Status, 2017* 21
  • Membranous Glomerulonephritis Therapeutics Clinical Trials, Global, by End Point Status, 2017* 22
  • Membranous Glomerulonephritis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 23
  • Membranous Glomerulonephritis Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2017* 24
  • Membranous Glomerulonephritis Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 25
  • Membranous Glomerulonephritis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 26
  • Membranous Glomerulonephritis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 27
Back to Top